Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EP0089 in advanced solid tumors
NCT07030478Phase 2Not yet recruiting
- Sponsor
- Ellipses Pharma
- Start
- Sep 2025
- Primary completion
- Mar 2028
- Modality
- Monoclonal Antibodies, Vaccines & Immunotherapeutics
01
Overview
A Phase 2 trial of EP0089 in solid tumor, sponsored by Ellipses Pharma. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
EP0089
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07030478.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07030478.